To ask the Secretary of State for Health and Social Care, what steps his Department and NHS England are taking to ensure continuity of care for patients affected by the recent court ruling in Bell v Tavistock.
This answer is the replacement for a previous holding answer.
29 December 2020
A full clinical review must be carried out for all patients under the age of 16 years old who are currently receiving puberty blockers. If the patient intends to continue on puberty blockers or progress onto cross sex hormones, the lead clinician must make a ‘best interests’ application to the Court for final determination of that individual’s needs. No patients will have puberty blockers withdrawn unless, as a result of the clinical review, a clinical decision, in consultation with the patient, is made to withdraw puberty blockers, or a court considers a ‘best interest’ decision and decides it is not in the patient’s interest to remain on puberty blockers.